$BDX

Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH

The article reviews post-earnings outlooks for four “Dividend Kings”: Becton Dickinson (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH). It cites quarterly results, cash flow, and updated FY26 guidance. BDX reported Q3 adjusted EPS $3.23 vs $3.14, ED Q2 EPS 83c vs 74c, EMR Q3 EPS $1.71 vs $1.68, and PH FY4 EPS $9.27 vs $8.29.

Original reporting
Published Aug 13, 2026, 6:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 12:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH — source image
Decision brief

The 30-second read

$BDXBullishMed
01

Why it matters

Traders can use the disclosed EPS beats, guidance range updates, and order/backlog and cash-flow metrics to gauge near-term estimate revision risk and relative momentum across the four names.

02

Market read

Among the four, EMR has the clearest combination of beat plus raised guidance and improving orders/margins, while ED is framed as stable but not a strong near-term setup.

03

What to watch

For BDX, the text notes margin pressure and portfolio transformation; for ED, purchased-power and fuel cost pressure could re-emerge; for PH, the excerpt truncates details that could matter for forward margin/cash-flow expectations.

Relevance 5/10Novelty 5/10Timing: after-hours/next-session positioning following last week’s earnings and guidance updates

Background

The piece is a multi-stock “Dividend Kings after earnings” roundup, using each company’s latest quarterly results and updated guidance to frame buy/sell/hold views.

Company-level read

Ticker impact

$BDXBullishMedium confidence
Context

BDX reported fiscal Q3 adjusted EPS of $3.23 vs $3.14 and tightened FY26 adjusted EPS outlook to $12.62-$12.72.

Expected impact

Near-term upside bias, but likely capped by the article’s “Hold” framing and valuation not described as stretched.

Evidence & confidence

The text provides concrete EPS/revenue beats and an updated guidance range, which are actionable for estimate revisions, but it does not indicate a major re-rating catalyst beyond the modest outlook tweak.

$EDNeutralMedium confidence
Context

ED posted Q2 adjusted EPS of $0.83 vs $0.74 and reaffirmed FY26 adjusted EPS guidance of $6.00-$6.20.

Expected impact

Limited directional conviction; expect range-bound trading unless analysts revise estimates upward beyond the reaffirmation.

Evidence & confidence

The beat and reaffirmation are real datapoints, yet the article explicitly says the near-term outlook is balanced and does not cite a surprise change in guidance.

$EMRBullishHigh confidence
Context

EMR’s fiscal Q3 adjusted EPS rose to $1.71 and management raised FY26 outlook to ~5% net sales growth and ~$6.55 adjusted EPS.

Expected impact

Higher probability of upward estimate revisions and follow-through buying versus the other names.

Evidence & confidence

The article includes multiple reinforcing datapoints: EPS beat, orders up, margin expansion, and explicit FY26 guidance increases plus cash flow and shareholder return expectations.

$PHBullishMedium confidence
Context

PH reported fiscal Q4 adjusted EPS of $9.27 vs $8.29 and said FY27 net sales and organic sales growth should be 5.5%-8.5%.

Expected impact

Potential for continued positive sentiment if the market treats the FY27 range as credible and margins/cash flow remain resilient.

Evidence & confidence

The text provides clear beats and a forward growth range, but the excerpt cuts off before detailing any additional margin or cash-flow guidance beyond what is already stated.

Market effects

Reinforces demand and margin resilience narratives in medical technology (BDX), industrial automation and instrumentation (EMR), and aerospace/industrial components (PH), while utilities (ED) remain rate-base and valuation sensitive.

No specific regional macro linkage beyond general rate/valuation sensitivity for utilities.

Limited; these are company-specific earnings and guidance disclosures with no stated global policy or cross-border shock.

Counterpoint

The article’s Zacks Rank #3 (Hold) for BDX and ED suggests the market may already price much of the “dividend king” quality, limiting upside despite beats.

Key entities

  • Becton, Dickinson and Company

    Reported fiscal Q3 adjusted EPS beat and tightened FY26 adjusted EPS outlook; continuing-business growth and cash flow improved.

  • Consolidated Edison

    Reported Q2 adjusted EPS and revenue beat, reaffirmed FY26 adjusted EPS guidance, and highlighted a large 2026-2030 capex plan.

  • Emerson Electric

    Reported fiscal Q3 EPS and revenue beats, showed improving orders and margins, and raised FY26 outlook with free cash flow expectations.

  • Parker-Hannifin

    Reported fiscal Q4 EPS and revenue beats, strong order growth, and provided FY27 sales growth and margin range guidance.

Related articles

$EMRMed

Does BP’s Shah Deniz Automation Deal Reframe Emerson’s Long‑Cycle Energy Narrative (EMR)?

BP awarded Emerson Electric a multi-million-dollar contract for the Shah Deniz Compression project, highlighting Emerson's role in long-cycle energy infrastructure. The deal supports Emerson's focus on automation and software, aligning with its Q2 guidance of 5% net sales growth. Analysts project $22.1B revenue and $3.8B earnings by 2029, with some expecting higher figures. Emerson's legacy energy exposure remains a risk.

$EMRMed

Spotting Winners: Trimble (NASDAQ:TRMB) And Internet of Things Stocks In Q2

Emerson Electric (NYSE:EMR) reported $4.87B revenue, up 7% YoY, beating expectations but missing on EBITDA. Vontier (NYSE:VNT) reported $756.7M revenue, down 2.2% YoY, beating expectations and raising guidance. Rockwell Automation (NYSE:ROK) reported $2.31B revenue, up 7.9% YoY, beating expectations. EMR and VNT stocks are down 1.8% and 2.4% since reporting, respectively, while ROK is down 9.4%.

$PHHighAI 8/10

Is Wall Street Bullish or Bearish on Parker-Hannifin Stock?

Parker-Hannifin (PH) reported Q4 2026 earnings with revenue of $5.8B, up 9.8% YoY, and adjusted EPS of $8.54, exceeding estimates. The stock has risen 36.8% over the past year, outperforming the S&P 500 and its industry benchmark. Analysts maintain a 'Strong Buy' consensus, with a mean price target of $1,175.38, suggesting a 17.5% upside.